

Claims:

Claim 1. Use of an inhibitor of ITFG1, in the manufacture of a medicament for treating or preventing a disease characterised by fibrosis; wherein the disease characterised by fibrosis is a liver disease or condition; wherein the inhibitor of ITFG1 is an inhibitory nucleic acid; and wherein the inhibitory nucleic acid is (i) an RNAi agent that reduces expression of ITFG1, or (ii) a nucleic acid encoding an RNAi agent that reduces expression of ITFG1.

Claim 2. The use according to claim 1, wherein the liver disease or condition is selected from: acute liver disease, chronic liver disease, metabolic liver disease, steatosis, liver fibrosis, primary sclerosing cholangitis (PSC), cirrhosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hepatic ischemia reperfusion injury, primary biliary cirrhosis (PBC), hepatitis, and liver damage, liver injury, liver failure, metabolic syndrome, obesity, diabetes mellitus, end-stage liver disease.

Claim 3. The use according to claim 2, wherein the liver fibrosis is virus-induced liver fibrosis.

Claim 4. The use according to claim 2, wherein the hepatitis is alcohol-induced hepatitis.

Claim 5. The use according to claim 2, wherein the liver damage is drug-induced liver damage or virus-induced liver damage.

Claim 6. The use according to any one of claims 1 to 5, wherein the RNAi agent that reduces expression of ITFG1 is an siRNA, shRNA, miRNA-based shRNA, or gRNA for CRISPR/CAS9 knockout.

Claim 7. The use according to any one of claims 1 to 6, wherein the RNAi agent is an siRNA.

Claim 8. The method use according to any one of claims 1 to 7, wherein the inhibitory nucleic acid comprises or encodes a nucleotide sequence having at least 90% sequence identity to any one of SEQ ID NO: 457 to 1482.

Claim 9. The use according to any one of claims 1 to 8, wherein the inhibitory nucleic acid is administered in the form of a vector comprising or encoding the inhibitory nucleic acid.

Claim 10. A method of regenerating liver tissue *in vitro*, the method comprising inhibiting ITFG1 in a cell of the tissue using an inhibitor of ITFG1; wherein the inhibitor of ITFG1 is an inhibitory nucleic acid; and wherein the inhibitory nucleic acid is (i) an RNAi agent that reduces expression of ITFG1, or (ii) a nucleic acid encoding an RNAi agent that reduces expression of ITFG1.

Claim 11. A method of proliferating/expanding a hepatocyte *in vitro*, the method comprising inhibiting ITFG1 in the hepatocyte using an inhibitor of ITFG1; wherein the inhibitor of ITFG1 is an inhibitory nucleic acid; and wherein the inhibitory nucleic acid is (i) an RNAi agent that reduces expression of ITFG1, or (ii) a nucleic acid encoding an RNAi agent that reduces expression of ITFG1.